According to the PRESTO tool, the risk of developing psoriatic arthritis in patients with psoriasis within 1 year was linked to a family history of psoriasis, joint or back stiffness, male sex, younger age, pain severity, and the use of biologic medications.
A cross-sectional analysis showed the reliability and repeatability of the Polish version of the Fibromyalgia Impact Questionnaire were "very good."
Changes in BMI were positively correlated with changes in IL-23 and significant positive correlations were observed between BMI and DAS28-CRP, CRP, IL-13, IL-17, leptin, and TNF-α.
The rheumatology month in review features studies exploring ways to enhance care, an increased risk of adverse COVID-19 outcomes, and pegloticase plus methotrexate co-therapy for gout treatment.
Tarun Sharma, MD, discusses the overarching trends in treating gout, predictions for the future, and the stigma that often surrounds a gout diagnosis.
The comprehensive score was able to recognize 119 high-risk participants (false positive rate of 29%) and 336 low-risk patients (false negative rate of 19%).
Common themes among patients and parents included a need to accurately assess pain and offer non-pharmacological options for pain management.
Patients with JPsA and concomitant psoriasis at diagnosis exhibited more depressive symptoms when compared with those without psoriasis.
All 30 neuropsychiatric symptoms included were significantly higher in patients with systemic autoimmune rheumatic diseases when compared with controls.
The median central sensitization, frequency of neuropathic pain, and frequency of fibromyalgia diagnosis were higher in patients with axSpA when compared with controls.
At months 6 and 12, tocilizumab retention rates were 94.1% and 86.6%, respectively.
In the updated analysis, the interleukin-23 p19-subunit inhibitor also showed better skin efficacy.
The risk of mortality was significantly higher in patients with RA treated with JAKs who had not received the COVID-19 vaccine.
Leveraging data from a pair of commercial databases, a new study details the changes in febuxostat prescribing among patients with gout before, during, and after the FDA's addition of a Boxed Warning to prescribing information.
Pediatric rheumatologists were most likely to postpone the decision to withdraw biologic therapy when the patient and/or parents expressed a preference for continuation.
The campaign was inspired by the findings of a global survey conducted with healthcare providers about organ damage in lupus patients.
A retrospective analysis of nearly 150 patients with gouty arthritis in China provides further insight into the relationship between pathological ultrasound features and clinical signs and symptoms among this patient population.
Women with psoriatic arthritis reported higher mean pain and worse mean patient global assessment when compared with men.
In this Q&A, Andrew Östör, MD, discussed the findings of a study that evaluated the one-year efficacy and safety of risankizumab in patients with inadequate response/intolerance to biologics or conventional synthetic DMARDs.
No statistically significant differences in retention rates were observed among those treated with baricitinib monotherapy or in combination with methotrexate.
At week 52, 58.5% of patients continuing risankizumab treatment and 55.7% of patients who switched to risankizumab at week 24 achieved ACR20.
An analysis of NHANES data is offering clinicians an overview of associations between hyperuricemia and gout with increased risk of mortality in patients with heart failure.
The pooled analysis showed the risk of all-cause dementia was decreased in patients with gout, particularly in patients receiving medication.
Although the benefits of telehealth are clear, it is not without its challenges. As the field of rheumatology moves into a post-pandemic world, the future of telemedicine hangs in the balance.
An increased hazard ratio was observed for all-cause mortality, including a standardized mortality ratio for accidents and an increased risk for mortality from infections and suicide.
Patients identified areas of confusion in data presentation and suggested educational support to better engage with the information provided.
Improvements in CDAI by >5 points were associated with improvements in the 5 PROMIS domains and increased satisfaction with rheumatoid arthritis treatment.
The rheumatology month in review features studies reporting increased depression rates among patients with autoimmune disease, interventions designed to decrease chronic pain symptoms in fibromyalgia, and highlights from EULAR 2023.
At month 12, response rate was significantly higher in patients receiving pegloticase and methotrexate when compared with concomitant placebo.
Of the randomized controlled trials identified, only 41% involved patients with depression.
